WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562364

CAS#: 912287-56-0

Description: YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2).

Price and Availability

Size Price Shipping out time Quantity
50mg USD 350 2 Weeks
100mg USD 550 2 Weeks
200mg USD 950 2 Weeks
500mg USD 1750 2 Weeks
1g USD 2950 2 Weeks
2g USD 4650 2 Weeks
5g USD 6850 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

YHO-13177, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 562364
Name: YHO-13177
CAS#: 912287-56-0
Chemical Formula: C20H22N2O3S
Exact Mass: 370.1351
Molecular Weight: 370.46
Elemental Analysis: C, 64.84; H, 5.99; N, 7.56; O, 12.96; S, 8.65

Synonym: YHO-13177; YHO 13177; YHO13177;

IUPAC/Chemical Name: (Z)-2-(3,4-Dimethoxyphenyl)-3-(5-(4-hydroxypiperidin-1-yl)thiophen-2-yl)acrylonitrile


InChi Code: InChI=1S/C20H22N2O3S/c1-24-18-5-3-14(12-19(18)25-2)15(13-21)11-17-4-6-20(26-17)22-9-7-16(23)8-10-22/h3-6,11-12,16,23H,7-10H2,1-2H3/b15-11+


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Zhang L, Zhao J, Liang C, Liu M, Xu F, Wang X. A novel biosensor based on intestinal 3D organoids for detecting the function of BCRP. Drug Deliv. 2017 Nov;24(1):1453-1459. doi: 10.1080/10717544.2017.1381199. PubMed PMID: 28949254.

2: Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R, Matsuzaki T, Yagi N, Sugimoto Y. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63. doi: 10.1158/1535-7163.MCT-10-0874. Epub 2011 May 12. PubMed PMID: 21566063.